Neurocrine Biosciences (NBIX) update #7
Posted by intelledgement on Tue, 17 Jun 08
Our “other”—the one that is not Vertex—development-stage biotech company, NBIX, announced today the completion of the treatment portion of their phase 2b study designed to assess the impact of their GnRH Antagonist elagolix (which is what the company are now calling NBI-56418) on bone mineral density (BMD).
Elagolix is intended a potential treatment for endometriosis, a common medical condition characterized by growth of tissue like endometrium, the lining of the uterus, beyond or outside the uterus. The BMD study is important because past attempts to deploy GnRH Antagonist treatments for endometriosis have been marked by signficant adverse effects on bone metabolism. The company believes that elagolix, a non-peptide GnRH, will be better tolerated than anything currently on the market.
According to the press release, the first data from the study should be available in September. Still no word on any partnership deals for elagolix, in case anyone besides us is still wondering.